百亿“抢亲”大战落幕!辉瑞力压诺和诺德,肥胖药赛道一夜变天

医药地理
Yesterday

一场围绕下一代肥胖药物的Metsera百亿并购案,演变为两大制药巨头的法律与资本对决。辉瑞如何在法庭受挫后,凭借监管智慧与加码报价,完成惊天逆转?诺和诺德的“闪电抢亲”为何最终功亏一篑?本文将完整梳理这场惊心动魄的收购大战全过程,从最初的“完美联姻”,到中途的突袭“抢亲”,再到双线法律战与反垄断升维打击,直至最后的闪电收官。这场大战不仅改写了一家公司的命运,更将重塑全球肥胖代谢药物市场的未来格局。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10